Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-135b
- Development stage
- Preclinical
- Lead developer
- Finnish Institute for Molecular Medicine
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
miR-135b is a microRNA that acts as a post-transcriptional regulator of gene expression. In the context of oncology, it has been shown to modulate the levels of androgen receptor (AR) and estrogen receptor (ER) in prostate and breast cancer cells, respectively. By targeting these receptors and other genes such as HIF1AN (Hypoxia-inducible factor 1-alpha inhibitor), miR-135b influences cell proliferation, oxygen homeostasis, angiogenesis, and glycolytic metabolism. Research suggests it may serve as a tumor suppressor or oncogene depending on the tissue context, but in the provided abstract, its overexpression inhibits growth in hormone-receptor-positive cancer cells.
- Other names
- hsa-miR-135bhsa-miR135bhsa-miR 135b
02
Targets
Adenomatous polyposis coli (APC) mRNANR (Nuclear receptors (steroid))Death-associated protein kinase 1 mRNA (DAPK1 mRNA)FOXO1 (Forkhead box protein O1)FIH-1 (Factor inhibiting hypoxia-inducible factor 1)RECK (Reversion-inducing cysteine-rich protein with Kazal motifs)TGFBR2 (TGF-β receptor type 2)AR (Adrenergic receptors)ER (Estrogen receptor)
Beyond the preview
Go deeper on miR-135b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-135b.